GCAR Names Meredith Buxton Chief Operating Officer
Company accelerates growth strategy with appointment of COO
LEXINGTON, Mass. (January 31, 2019). Global Coalition for Adaptive Research (“GCAR”), a non-profit organization working to speed the discovery and development of cures for rare and deadly diseases starting with one of the most deadly brain cancers - glioblastoma (GBM) – today announced the appointment of Meredith Buxton, Ph.D., M.P.H., as Chief Operating Officer, effectively immediately.
“After a competitive national search, we are honored to welcome Dr. Buxton to the GCAR team,” shared Faramarz Yousefzadeh, Chairman of the Board of Directors. “Meredith’s diverse and rich experience and her unique skills in adaptive and platform trial operational design and implementation will help deliver on GCAR’s mission to create a powerful new platform to transform stories of loss into prolonged life.”
Prior to joining GCAR, Dr. Buxton was Director of Clinical Trial Strategy for Berry Consultants, where she provided strategic guidance and implementation expertise for several master protocols by pharma and nonprofit sponsors. Previously, Dr. Buxton was Assistant Professor at University of California, San Francisco and Executive Director of the I-SPY TRIALs Consortium, platform trials using scientific and process innovation to test new drugs for breast cancer. Dr. Buxton earned an undergraduate degree at Stanford University and completed a Master’s in Public Health and PhD in Epidemiology from Columbia University.
“I am honored that GCAR’s leadership and board have entrusted me to lead the organization as COO and launch GBM AGILE as its flagship project,” said Dr. Buxton. “GBM is a complex, difficult disease. While the understanding of GBM biology has increased dramatically over the past decade, this understanding has not yet led to improvements in survival for patients with the disease. This challenging state of affairs for GBM patients became the impetus for creating GCAR and GBM AGILE. I am committed to the organization’s vision to expand and replicate what is learned from GBM AGILE to benefit patients with other rare and deadly diseases.”
About Global Coalition for Adaptive Research
GCAR is a 501(c)(3) non-profit organization, comprised of some of the world’s foremost physicians, clinical researchers and investigators united in expediting the discovery and development of cures for patients with rare and deadly diseases. As its first priority, GCAR is sponsoring GBM AGILE, an adaptive platform trial for patients with glioblastoma (GBM). GCAR’s vision is to expand and replicate what is learned using this innovative model for glioblastoma to benefit patients with other rare and deadly diseases. Join us by following us: @GCAResearch and www.facebook.com/GCAResearch. To learn more, visit: www.gcaresearch.org